Recursion Pharmaceuticals Inc.
Organization details
- Legal name
- Recursion Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Salt Lake City
- Headquarters state / province
- Utah
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RXRX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001601830
- EIN
- 46-4099738
Board of directors
-
Blake Borgeson · DirectorSince 2023
-
Christopher Gibson · Director · Chief Executive OfficerSince 2023
-
Dean Y. Li · DirectorSince 2023
-
Elaine D. Sun · DirectorSince 2025
-
Franziska Michor · DirectorSince 2024
- Since 2026
-
Najat Khan · Director · CEO and PresidentSince 2024
-
Namandje Bumpus · DirectorSince 2025
-
R. Martin Chavez · DirectorSince 2023
-
Robert Hershberg · DirectorSince 2023
-
Terry-Ann Burrell · DirectorSince 2023
-
Zachary Bogue · DirectorSince 2023
-
Zavain Dar · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.3%
-
88.3%
Board connections
5 of this board's directors also sit on 10 other boards. 6 are in the same sector.
-
Adaptive Biotechnologies Corporation Same sectorvia Robert Hershberg
- via R. Martin Chavez
-
BridgeBio Pharma Inc. Same sectorvia Fred Hassan
-
Cocrystal Pharma Inc. Same sectorvia Fred Hassan
- via Robert Hershberg
- via Fred Hassan
-
Fate Therapeutics Inc. Same sectorvia Robert Hershberg
- via Christopher Gibson
-
Precigen Inc. Same sectorvia Fred Hassan
-
Rapport Therapeutics Inc. Same sectorvia Terry-Ann Burrell
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $7,597,469
- 35 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Blake Borgeson Director | Open-market sale | −40,000 | $3.88 | $155,200 |
| Nov 2, 2026 | Fred Hassan Director | Grant or award | +156,658 | — | — |
| Oct 6, 2026 | Blake Borgeson Director | Open-market sale | −50,000 | $4.84 | $242,000 |
| Oct 6, 2026 | Robert Hershberg Director | Option exercise | +25,000 | $2.22 | $55,500 |
| Oct 6, 2026 | Robert Hershberg Director | Open-market sale | −25,000 | $5.00 | $125,000 |
| Oct 1, 2026 | Zavain Dar Director | Grant or award | +4,607 | — | — |
| Oct 1, 2026 | Dean Y. Li Director | Grant or award | +3,378 | — | — |
| Sep 15, 2026 | Taylor Ben R Officer (Chief Financial Officer) | Shares withheld for tax | −5,396 | $3.41 | $18,400 |
| Sep 8, 2026 | Najat Khan Director, Officer (CEO and President) | Open-market sale | −22,408 | $3.52 | $78,876 |
| Sep 1, 2026 | Blake Borgeson Director | Open-market sale | −30,000 | $3.34 | $100,200 |
| Aug 17, 2026 | Hallett David Officer (Chief Scientific Officer) | Shares withheld for tax | −26,657 | $3.16 | $84,236 |
| Aug 17, 2026 | Najat Khan Director, Officer (CEO and President) | Shares withheld for tax | −80,498 | $3.16 | $254,374 |
| Aug 17, 2026 | Taylor Ben R Officer (Chief Financial Officer) | Shares withheld for tax | −25,018 | $3.16 | $79,057 |
| Aug 4, 2026 | Blake Borgeson Director | Open-market sale | −30,000 | $3.25 | $97,500 |
| Jul 7, 2026 | Blake Borgeson Director | Open-market sale | −40,000 | $3.96 | $158,400 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Recursion Pharmaceuticals Inc.
Who is the CEO of Recursion Pharmaceuticals Inc.?
Christopher Gibson is Recursion Pharmaceuticals Inc.'s Chief Executive Officer.
How many directors are on Recursion Pharmaceuticals Inc.'s board?
Recursion Pharmaceuticals Inc.'s board has 13 directors: Blake Borgeson, Christopher Gibson, Dean Y. Li, Elaine D. Sun, Franziska Michor, Fred Hassan, Najat Khan, Namandje Bumpus, R. Martin Chavez, Robert Hershberg and 3 others.
Are Recursion Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, Recursion Pharmaceuticals Inc. insiders made no open-market purchases and sold $7.6 million of shares in 35 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="recursion-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.